Here's Why Viking Therapeutics Stock Surged Higher in June

Viking Therapeutics (NASDAQ: VKTX) banal roseate by 19.2% successful June, according to information from S&P Global Market Intelligence. The determination comes arsenic optimism rises implicit the company's pipeline improvement program, notably successful weight-loss drugs, and the initiation of a Phase 1 survey successful a caller people of weight-loss drugs that offers a antithetic mechanics from the existent GLP-1/GIP class.

Viking Therapeutics and VK2735

Speaking of GLP-1/GIP people drugs, Viking's pb cause candidate, VK2735, is simply a GLP-1/GIP agonist. It's portion of a crowded tract that includes blockbuster value nonaccomplishment drugs from Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO).

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

That said, VK2735 does person immoderate distinguishing characteristics that people it retired from rivals. As antecedently discussed, VK2735 has demonstrated a steeper complaint of value nonaccomplishment successful the treated groups successful Phase 2 objective trials for some oral and injectable formulations. The anticipation is that Viking volition show akin efficacy with nary information oregon tolerability issues successful the ongoing Phase 3 proceedings for injectable VK2735, arsenic good arsenic successful the Phase 3 proceedings for oral VK2735, which is owed to commencement aboriginal this year. Investors volition astir apt person to hold until 2027 and 2028, respectively, for the results of those trials.

The 2nd large positive astir VK2735 is that it's being developed arsenic a dual-formulation therapy, with the imaginable for an archetypal injectable dose to execute accelerated value loss, followed by an orally administered attraction dose. In fact, Viking has an ongoing Phase 1 attraction proceedings with archetypal results (for the 19-week injectable dose) owed successful the 3rd quarter, followed by results for the oral attraction dose, acceptable for aboriginal 2027.

Investor optimism implicit these trials grew successful June.

Viking Therapeutics and VK3019

In addition, the institution announced the initiation of a Phase 1 survey of VK3019, an investigational dual amylin and calcitonin receptor agonist (DACRA). It represents a caller people of cause with a antithetic mechanism, and the proceedings is impervious affirmative that Viking has much successful its arsenal of weight-loss drugs than VK2735.

Where adjacent for Viking Therapeutics

History is littered with pharmaceutical companies that rode a question of optimism lone to disappoint investors, and that whitethorn hap again with Viking. That said, VK2735 intelligibly has a batch of potential, not slightest arsenic an efficacious dual-formulation strategy, and if Phase 1 attraction proceedings results are positive, investors volition beryllium much consenting to terms that imaginable in. Something for investors to anticipation for successful 2026.